Companies Allakos
Allakos (ALLK): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Allakos no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers77th pct.Of 18 peer CEOs
CEO pay, last three years
- $10,988,477FY2021
- $7,366,205FY2022
- $6,299,426FY2023
CEO total pay was $6,299,426 in fiscal 2023, down from $7,366,205 in fiscal 2022.
FY2023: salary $805,460 · bonus $0 · stock awards $2,171,340 · option awards $2,623,519
Executives and directors
Baird Radford · CFORobert Alexander · CEOAdam Tomasi · PresidentAmy L. Ladd · Independent DirectorDaniel Janney · Chair of the BoardDolca Thomas · Independent DirectorE. Rand Sutherland · Independent DirectorJohn McKearn · Former director (through FY2023)Neil Graham · Independent DirectorPaul Walker · Independent DirectorRobert E. Andreatta · Independent DirectorSteven P. James · Independent Director
Frequently asked questions
Who was the highest-paid executive at Allakos in fiscal 2023?
As disclosed, Robert Alexander (Chief Executive Officer and Director) was the highest-paid executive at Allakos in fiscal 2023, with total compensation of $6,299,426.
How does Allakos's chief executive pay compare to its disclosed peer group?
As disclosed, Robert Alexander's total compensation ranked at the 77th percentile of Allakos's disclosed peer group.
What is Allakos's CEO-to-median employee pay ratio?
As disclosed, Allakos's CEO-to-median employee pay ratio was 33:1.
How did shareholders vote on Allakos's executive compensation?
As disclosed, 85.47% of shareholders supported Allakos's executive compensation in the latest say-on-pay vote.
How much does Allakos spend in total on board compensation for fiscal 2023?
As disclosed, Allakos reported total board compensation of $442,916 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Alexander | $805,460 | $0 | $2,171,340 | $2,623,519 | $684,641 | $0 | $14,466 | $6,299,426 |
| Chief Executive Officer and Director | ||||||||
| Adam Tomasi | 709,670 | 0 | 1,411,178 | 1,705,059 | 425,802 | 0 | 14,466 | 4,266,175 |
| President | ||||||||
| Baird Radford | 494,400 | 0 | 911,808 | 1,101,693 | 222,480 | 0 | 14,466 | 2,744,847 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Robert Alexander | $6,299,426 | $7,366,205 | $10,988,477 | ↓ −1,066,779 |
| Adam Tomasi | 4,266,175 | 4,954,370 | 7,258,214 | ↓ −688,195 |
| Baird Radford | 2,744,847 | 3,359,965 | 6,018,813 | ↓ −615,118 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The guiding principle in the development of our compensation strategy is to create and nurture a pay-for-performance culture, where contributions to enhancing stockholder value have the potential to be matched with appropriate financial rewards.
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | True |
| Anti-hedging | False |
| Anti-pledging | False |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Adam Tomasi | OPTION | 2023-01-06 | — | — | 300,471 | — | $1,705,059 |
| Robert Alexander | RSU | 2023-01-06 | — | — | 301,575 | — | 2,171,340 |
| Baird Radford | OPTION | 2023-01-06 | — | — | 194,144 | — | 1,101,693 |
| Adam Tomasi | RSU | 2023-01-06 | — | — | 195,997 | — | 1,411,178 |
| Robert Alexander | OPTION | 2023-01-06 | — | — | 462,325 | — | 2,623,519 |
| Baird Radford | RSU | 2023-01-06 | — | — | 126,640 | — | 911,808 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Adam Tomasi | $1,411,178 | $0 | $1,705,059 | 0.0% |
| Robert Alexander | 2,171,340 | 0 | 2,623,519 | 0.0% |
| Baird Radford | 911,808 | 0 | 1,101,693 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Baird Radford | RSU | 6,413 | — | $17,507 |
| Baird Radford | Option | 9,200 | 105.16 | — |
| Adam Tomasi | PSU | 11,121 | — | 30,360 |
| Baird Radford | RSU | 12,128 | — | 33,109 |
| Adam Tomasi | RSU | 16,681 | — | 45,539 |
| Robert Alexander | PSU | 17,227 | — | 47,030 |
| Adam Tomasi | RSU | 19,625 | — | 53,576 |
| Robert Alexander | RSU | 25,841 | — | 70,546 |
| Robert Alexander | RSU | 30,400 | — | 82,992 |
| Baird Radford | RSU | 126,640 | — | 345,727 |
| Baird Radford | RSU | 133,655 | — | 364,878 |
| Adam Tomasi | RSU | 193,534 | — | 528,348 |
| Baird Radford | Option | 194,144 | 7.2 | — |
| Adam Tomasi | RSU | 195,997 | — | 535,072 |
| Baird Radford | PSU | 237,608 | — | 648,670 |
| Robert Alexander | RSU | 297,745 | — | 812,844 |
| Adam Tomasi | Option | 300,471 | 7.2 | — |
| Robert Alexander | RSU | 301,575 | — | 823,300 |
| Adam Tomasi | PSU | 344,060 | — | 939,284 |
| Robert Alexander | Option | 462,325 | 7.2 | — |
| Robert Alexander | PSU | 529,323 | — | 1,445,052 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| E. Rand SutherlandIndependent · Research and Clinical Development · Not standing for re-election | $18,333 | $0 | $714,142 | — | $0 | $732,475 |
| Dolca ThomasIndependent · Research and Clinical Development | 18,333 | 0 | 714,142 | — | 0 | 732,475 |
| Daniel JanneyIndependent · Board Chair · Compensation · Corporate Governance and Nominating (Chair) · Not standing for re-election | 112,500 | 0 | 322,117 | — | 0 | 434,617 |
| Robert E. AndreattaIndependent · Audit (Chair) · Corporate Governance and Nominating | 67,500 | 0 | 322,117 | — | 0 | 389,617 |
| Paul WalkerIndependent · Audit · Compensation | 65,000 | 0 | 322,117 | — | 0 | 387,117 |
| Steven P. JamesIndependent · Audit · Corporate Governance and Nominating | 65,000 | 0 | 322,117 | — | 0 | 387,117 |
| Neil GrahamIndependent · Research and Clinical Development | 13,750 | 0 | 364,525 | — | 0 | 378,275 |
| Amy L. LaddIndependent · Compensation · Corporate Governance and Nominating | 50,000 | 0 | 322,117 | — | 0 | 372,117 |
| John McKearnIndependent · Departed during FY | 32,500 | 0 | — | — | 0 | 32,500 |
| Robert AlexanderEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $47,500 |
|---|---|
| Annual equity retainer | $296,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $442,916 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $442,916 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Allakos as a peer
Companies that benchmark against ALLK
4 companies name ALLK as a compensation peer
The list of companies that name ALLK as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ANNX Annexon, Inc.PMVP PMV Pharmaceuticals, Inc. Evelo Biosciences, Inc.ALEC Alector, Inc.MRSN Mersana Therapeutics, Inc.ALLO Allogene Therapeutics, Inc.COGT Cogent Biosciences, Inc. Tricida, Inc.IMVT Immunovant, Inc.ANAB AnaptysBio, Inc.CLDX Celldex Therapeutics, Inc.FULC Fulcrum Therapeutics, Inc. Gossamar Bio, Inc.KNSA Kiniksa Pharmaceuticals, Ltd.KOD Kodiak Sciences Inc.OMER Omeros CorporationOTLK Outlook Therapeutics, Inc. Piant Therapeutics, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences, Inc. | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Immunovant, Inc. | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | Kiniksa Pharmaceuticals, Ltd. | 2025 | Sanj Patel | 943,129 | 3,798,021 | 4,743,446 | 1,284,065 | 10,782,661 |
| 4 | Allakos | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 5 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 6 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 7 | Celldex Therapeutics, Inc. | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 8 | Omeros Corporation | 2025 | Gregory Demopulos | 972,525 | 0 | 2,207,974 | 0 | 4,178,008 |
| 9 | Annexon, Inc. | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 10 | Fulcrum Therapeutics, Inc. | 2025 | Alex Sapir | 650,000 | 0 | 2,052,132 | 411,200 | 3,251,490 |
| 11 | Kodiak Sciences Inc. | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 12 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 13 | PMV Pharmaceuticals, Inc. | 2025 | David Mack | 628,461 | 0 | 752,320 | 284,410 | 1,665,191 |
| 14 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| — | Outlook Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Allakos | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Annexon, Inc. | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Celldex Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Cogent Biosciences, Inc. | 135% | not disclosed | No | Compensia |
| Fulcrum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| Kiniksa Pharmaceuticals, Ltd. | not disclosed | Option 50 · RSU 25 · PSU 25 | not disclosed | Compensia, Inc. |
| Kodiak Sciences Inc. | 150% | not disclosed | not disclosed | Compensia, Inc. |
| Mersana Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Omeros Corporation | not disclosed | Option 100 | not disclosed | Compensia |
| Outlook Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| PMV Pharmaceuticals, Inc. | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-05-24 | 57,581,186 | 9,731,502 | 56,969 | 85.47% | Passed |
| 2021 | 2021-05-25 | 19,865,652 | 28,179,012 | 4,063 | 41.35% | Failed |
| 2019 | 2019-06-06 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-05-24 | 85.47%a |
| 2021 | 2021-05-25 | 41.35%b |
| 2019 | 2019-06-06 | —c |
a. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote AGAINST this proposal.”.
b. Approved under the standard stated in the filing — “On other matters submitted for a vote, broker 3 Table of Contents non-votes will not be considered in tallying votes cast, and abstentions will be treated as a vote "against." If less than a majority of the combined voting power of the outstanding shares of common stock is represented at the 202 1 Annual Meeting, a majority of the shares so represented may adjourn the 202 1 Annual Meeting from time to time without further notice.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 33 : 1 |
|---|---|
| CEO total compensation | $10,988,477 |
| Median employee compensation | $336,570 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Baird Radford | Chief Financial Officer | 2025-03-05 | D | 14,161 | $0 | $3,682 | Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-03-05 | D | 20,017 | 0 | 5,204 | Common | Form 4 ↗ |
| Robert Alexander | Director | 2025-03-06 | D | 31,370 | 0 | 8,156 | Common | Form 4 ↗ |
| Neil Graham | Director | 2025-05-15 | D | 154,786 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Baird Radford | Chief Financial Officer | 2025-05-15 | D | 194,144 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 41,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 3,386,400 | — | — | Common, indirect | Form 4 ↗ |
| BVF PARTNERS L P/IL | Greater-than-10% holder | 2025-05-15 | D | 855,211 | — | — | Common, indirect | Form 4 ↗ |
| Robert Alexander | Director | 2025-05-15 | D | 462,325 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Alexander | Director | 2025-05-15 | D | 250,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Alexander | Director | 2025-05-15 | D | 306,960 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Alexander | Director | 2025-05-15 | D | 290,022 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Alexander | Director | 2025-05-15 | D | 912,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Alexander | Director | 2025-05-15 | D | 738,104 | — | — | Common | Form 4 ↗ |
| Robert E. Andreatta | Director | 2025-05-15 | D | 37,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Graham | Director | 2025-05-15 | D | 41,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven P. James | Director | 2025-05-15 | D | 86,762 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven P. James | Director | 2025-05-15 | D | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven P. James | Director | 2025-05-15 | D | 55,380 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Baird Radford | Chief Financial Officer | 2025-05-15 | D | 27,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Baird Radford | Chief Financial Officer | 2025-05-15 | D | 163,426 | — | — | Common | Form 4 ↗ |
| Dolca Thomas | Director | 2025-05-15 | D | 41,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-05-15 | D | 125,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 86,762 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 99,590 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 37,600 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Greater-than-10% holder | 2025-05-15 | D | 6,777,935 | — | — | Common, indirect | Form 4 ↗ |
| BVF PARTNERS L P/IL | Greater-than-10% holder | 2025-05-15 | D | 8,679,726 | — | — | Common, indirect | Form 4 ↗ |
| Paul Walker | Director | 2025-05-15 | D | 2,760,860 | — | — | Common, indirect | Form 4 ↗ |
| Robert Alexander | Director | 2025-05-15 | D | 2,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven P. James | Director | 2025-05-15 | D | 99,590 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven P. James | Director | 2025-05-15 | D | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven P. James | Director | 2025-05-15 | D | 18,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven P. James | Director | 2025-05-15 | D | 41,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven P. James | Director | 2025-05-15 | D | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dolca Thomas | Director | 2025-05-15 | D | 154,786 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy L. Ladd | Director | 2025-05-15 | D | 233,177 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy L. Ladd | Director | 2025-05-15 | D | 41,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy L. Ladd | Director | 2025-05-15 | D | 86,762 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Andreatta | Director | 2025-05-15 | D | 99,590 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Andreatta | Director | 2025-05-15 | D | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Andreatta | Director | 2025-05-15 | D | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Andreatta | Director | 2025-05-15 | D | 41,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Andreatta | Director | 2025-05-15 | D | 86,762 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Andreatta | Director | 2025-05-15 | D | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Alexander | Director | 2025-05-15 | D | 320,300 | — | — | Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-05-15 | D | 512,630 | — | — | Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-05-15 | D | 1,200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-05-15 | D | 300,471 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-05-15 | D | 145,011 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-05-15 | D | 88,036 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-05-15 | D | 486,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Tomasi | President | 2025-05-15 | D | 20,790 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (96 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Robert Alexander. DEF 14A, filed 2024-04-23. Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 6,299,426. View filing ↗
- Section 01, Adam Tomasi. DEF 14A, filed 2024-04-23. Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 4,266,175. View filing ↗
- Section 01, Baird Radford. DEF 14A, filed 2024-04-23. Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 2,744,847. View filing ↗
- Section 03, Adam Tomasi OPTION. DEF 14A, filed 2024-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Alexander RSU. DEF 14A, filed 2024-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Baird Radford OPTION. DEF 14A, filed 2024-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Adam Tomasi RSU. DEF 14A, filed 2024-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Alexander OPTION. DEF 14A, filed 2024-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Baird Radford RSU. DEF 14A, filed 2024-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2022-04-14. Section “CEO Pay Ratio”. As printed: 33 : 1. View filing ↗
- Section 08, E. Rand Sutherland. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 732,475. View filing ↗
- Section 08, Dolca Thomas. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 732,475. View filing ↗
- Section 08, Daniel Janney. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 434,617. View filing ↗
- Section 08, Robert E. Andreatta. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 389,617. View filing ↗
- Section 08, Paul Walker. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 387,117. View filing ↗
- Section 08, Steven P. James. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 387,117. View filing ↗
- Section 08, Neil Graham. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 378,275. View filing ↗
- Section 08, Amy L. Ladd. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 372,117. View filing ↗
- Section 08, John McKearn. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 32,500. View filing ↗
- Section 08, Robert Alexander. DEF 14A, filed 2024-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Baird Radford 2025-03-05. Form 4, filed 2025-03-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-03-05. Form 4, filed 2025-03-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-03-06. Form 4, filed 2025-03-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Neil Graham 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Baird Radford 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert E. Andreatta 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Neil Graham 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven P. James 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven P. James 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven P. James 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Baird Radford 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Baird Radford 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dolca Thomas 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Walker 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven P. James 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven P. James 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven P. James 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven P. James 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven P. James 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dolca Thomas 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy L. Ladd 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy L. Ladd 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Amy L. Ladd 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert E. Andreatta 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert E. Andreatta 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert E. Andreatta 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert E. Andreatta 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert E. Andreatta 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert E. Andreatta 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Alexander 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Tomasi 2025-05-15. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-28. Item 5.07 · say-on-pay result. As reported: 85.47% (votes for as printed: 57,581,186). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-05-26. Item 5.07 · say-on-pay result. As reported: 41.35% (votes for as printed: 19,865,652). View filing ↗
- Section 06, 2019 vote. Form 8-K, filed 2019-06-10. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 442,916 + equity 0 + all other 0 = 442,916, summed across the director compensation table rows.
- Cogent Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences, Inc.'s own proxy. As printed: 27,762,684. View filing ↗
- Immunovant, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. View filing ↗
- Kiniksa Pharmaceuticals, Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Kiniksa Pharmaceuticals, Ltd.'s own proxy. As printed: 10,782,661. View filing ↗
- Allakos (subject), Section 10b CEO total. DEF 14A, filed 2024-04-23. CEO total compensation as printed in Allakos's own proxy. As printed: 6,299,426. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- AnaptysBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- Celldex Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. View filing ↗
- Omeros Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Omeros Corporation's own proxy. As printed: 4,178,008. View filing ↗
- Annexon, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Annexon, Inc.'s own proxy. As printed: 3,579,202. View filing ↗
- Fulcrum Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. View filing ↗
- Kodiak Sciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
- PMV Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in PMV Pharmaceuticals, Inc.'s own proxy. As printed: 1,665,191. View filing ↗
- Mersana Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. View filing ↗